Our study suggests the core clock component PER2 as a novel common drug target for management of GHPA and PRLPA because PER2 acts as a pro-oncogenic protein for these two types of pituitary adenomas and the small molecule SR8278 decreases PER2 expression and mitigates tumor growth. This evidence concerns the gene PER2 and neoplasm.